// App-Quantinova.ai

1149 : Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Researchers

Presenter

  • Nathan H Fowler

Principal Investigators

  • Martin Dreyling

  • Joaquin Martinez-Lopez

  • Arne Kolstad

  • Jason P Butler

  • Monalisa Ghosh

  • Leslie L. Popplewell

  • Julio C. Chavez

  • Emmanuel Bachy

  • Koji Kato

  • Hideo Harigae

  • Marie Jos Kersten

  • Charalambos Andreadis

  • Peter A. Riedell

  • P. Joy Ho

  • Jose Antonio Prez-Simn

  • Sarah J. Nagle

  • Loretta J. Nastoupil

  • Bastian von Tresckow

  • Andres JM Ferreri

  • Takanori Teshima

  • Piers Patten

  • Joseph P. McGuirk

  • Andreas Petzer

  • Fritz Offner

  • Andreas Viardot

  • Pier Luigi Zinzani

  • Ram Malladi

  • Lida Bubuteishvili Pacaud

  • Alessandra Forcina

  • Aiesha Zia

  • Stephen J. Schuster

  • Catherine Thieblemont

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • BostonGene, LLC, Waltham, MA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Medizinische Klinik III, LMU Klinikum,Munich,Germany

  • Hospital12 de Octubre, Complutense University of Madrid, Madrid, Spain

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • School of Medicine, University of Michigan, Ann Arbor, MI

  • City of Hope, Duarte, CA

  • Moffitt Cancer Center, Tampa, FL

  • Hospices Civils de Lyon & Universite Claude Bernard Lyon-Est, Lyon, France

  • Fukuoka University Hospital, Fukuoka, Japan

  • Tohoku University, Miyagi, Japan

  • Amsterdam University Medical Centers, University of Amsterdam, Cancer Center

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • The University of Chicago Medical Center, Chicago, IL

  • Royal Prince Alfred Hospital and University of Sydney, New South Wales, Australia

  • Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CISC/CIBERONC). Universidad de Sevilla,Sevilla,Spanien

  • Oregon Health and Science University, Portland, OR

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany

  • Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

  • IRCCS Ospedale San Raffaele, Milan, Italy

  • Hokkaido University Hospital, Sapporo, Japan

  • King’s College Hospital/Kings College London United Kingdom

  • University of Kansas Medical Center, Westwood, KS

  • Internal Medicine I, Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria

  • UZ Ghent, Ghent, Belgium

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • University of Pennsylvania, Philadelphia, PA

  • Hospital Saint Antoine, Paris, France

Locations

  • United States

  • Australia

  • Germany

  • Spain

  • Norway

  • France

  • Japan

  • Netherlands

  • Italy

  • United Kingdom

  • Austria

  • Belgium

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • tisagenlecleucel-t

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved